Danco seeks Supreme Court

Pharmaceutical company Danco Laboratories filed an application with the U.S. Supreme Court on Saturday seeking a stay of an appeals court ruling that temporarily blocks the abortion drug mifepristone from being dispensed through the mail.



The appeals court ruling was issued unanimously by a conservative three-judge panel on Friday, significantly curtailing access to the drug nationwide and particularly in states that have banned abortion.



The temporary decision was made in a case brought by Republican-led state of Louisiana claiming the FDA in adopting a 2023 rule - which allows mifepristone to be dispensed through the mail - had ignored the risks of serious adverse events posed by the drug, including sepsis and hemorrhaging.



The panel ruled that Louisiana was likely to prevail in its challenge. Danco, in its Supreme Court application, said the ruling "injects immediate confusion and upheaval into highly time-sensitive medical decisions—and it forces Danco, FDA, certified Mifeprex providers, patients, and pharmacies all to guess at what is allowed and what is not."